Monthly Archives: July 2017

Jeff Broin, CEO of POET, the worlds leading producer of biofuels, received the George Washington Carver Award at a July 24 ceremony at the BIO World Congress in Montreal. The Carver Award recognizes significant contributions by individuals in the field of industrial biotechnology and its application in biological engineering, environmental science, biorefining and biobased products.

I am very humbled by this award. George Washington Carver was an historic leader in finding new potential in agricultural products to meet the worlds needs, Broin said. Thats what we strive to do each day at POET, whether its producing biofuel from starch and cellulose or finding new or better ways to produce co-products such as distillers grain, corn oil, fiber, liquefied CO2 and more. I believe agriculture is the key to solving many of our worlds challenges.

Related: POET DSM Opens First Commercial Cellulosic Ethanol Plant in the U.S.

Creating new markets for ag products

Carver was a true visionary," Broin said. "At POET, we follow that vision, developing additional products and bioprocesses to replace petroleum-based products. We believe the agricultural potential of the world is virtually untapped. The world is beginning to learn that we need to return to the sun, the soil and the seed.

Jeff Broin is one of the great innovators and entrepreneurs in the industrial biotechnology sector, said Brent Erickson, executive vice president of BIOs Industrial & Environmental Section. He ranks among the most influential leaders in agriculture as well. Biofuels have created new markets for agricultural products and rejuvenated rural America. Jeff Broin has positioned POET at the forefront of developing cellulosic ethanol and improving the economics of biofuel production.

As POET CEO, Broin grew the company from a 1-million-gallon-per-year facility in 1987 into the world's largest biofuels producer, with 1.8 billion gallons of annual fuel production and 10 billion pounds of high-protein animal feed, among other products.

Success in developing new technology

Broin says POET has always placed a high priority on research, from the laboratories at its headquarters in Sioux Falls, South Dakota, to its pilot plant/research facility in Scotland, South Dakota, to its commercial-scale demonstration cellulosic biofuel plant in Emmetsburg, Iowa, as part of POET-DSM Advanced Biofuels. This focus has led to industry-leading technology such as BPX (POETs proprietary no-cook production process), total water recovery technology, unique corn oil and distillers grains products, cellulosic biofuel development and more.

The George Washington Carver Award is also sponsored by the Iowa Biotechnology Association. Joe Hrdlicka, executive director of the Iowa Biotechnology Association, said, Jeff Broin has created an environment at POET where new ideas thrive throughout the value chain of new economic opportunities for American agricultural producers and rural communities. His business model truly reflects the ideas and passion spawned by George Washington Carver a century ago.

Past Carver Award Recipients:

See the original post here:
Jeff Broin receives George Washington Carver Award - Wallace's Farmer

Just as smaller animals of a given species generally live longer than their larger cousins, one might expect that taller humans are genetically programmed to sacrifice longevity for height.

But its not that simple.

A major multinational study of 841 men and women from across four populations found lower levels of insulin-like growth factor 1 (IGF-1) in men living to age 100 and yet most of them were taller than men in the younger control group.

The apparent explanation for this head-scratcher is that some long-lived men and only men have a genetic mutation that makes their growth hormone receptors more sensitive to the effects of the hormone. The cells absorb less growth hormone, yet protein expression is increased by several times.

This mutation seems to be responsible for their ability to live about 10 years longer than the control group of 70-year-old men without the mutation, even though they have a lower amount of growth hormone and are about 3 centimeters (1.18 inches) taller.

The lead author of the study is Prof. Gil Atzmon of Albert Einstein College of Medicine in New York and head of the Laboratory of Genetics and Epigenetics of Aging and Longevity at the University of Haifa. Since 2001, Atzmon has been studying the human genome and its impact on aging and longevity.

Longevity genes

The researchers working with Atzmon looked at four elderly populations: 567 Ashkenazi Jews in the Longevity Genes Project at Einstein, 152 from a study of Amish centenarians, and the rest from an American cardiovascular health study and a French longevity study.

In 2008, the Longevity Genes Project found a genetic mutation in the IGF-1 receptor of some women, though its not the same as the one affecting mens lifespan.

We knew in the past that genetic pathways associated with growth hormone were also associated with longevity and now we have found a specific mutation whose presence or absence is directly related to it, said Atzmon.

This study makes it an established fact that there is a relationship between the function of the growth hormone and longevity. Our current goal is to fully understand the mechanism of the mutation we found to express it, so that we can allow longevity while maintaining quality of life, he added.

The 16 researchers involved the study, published June 16 in Science Advances, are associated with institutions in Israel and France as well as the US states of New York, Maryland, California, Vermont, Massachusetts and Washington.

Clue to longer life

While more research is needed to understand why the receptor mutation affects longevity and why it happens only in men, the study suggests that making a slight change in this specific piece of DNA could possibly make people live longer.

Although the presence of the mutation almost certainly ensured longevity, Atzmon stressed that many other factors affect longevity and that many men without the mutation also live to 100 and older.

Atzmon is one of the principal researchers in the Longevity Genes Project at Einstein along with Israeli endocrinology specialist Dr. Nir Barzilai.

Their groundbreaking 10-year study of healthy Ashkenazi Jews between the ages of 95 and 112 and their children attempted to understand why humans dont all age at the same rate, and why only one in 10,000 individuals lives to 100.

The centenarians were found to have genetic protective factors (longevity genes) that overcame factors such as diet and lifestyle.

View original post here:
Mutation explains why some men live to 100 - ISRAEL21c

10 A.M.It is hot and sultry in the slums of the Campina Barreto neighborhood on the north side of Recife, in Brazil, and a public health worker named Glaucia has just taken a blood sample from a young, pregnant patient. Glaucia feeds it into a portable sequencer the size of a USB stick, plugs the sequencer into her computer and waits for the results. The device identifies genetic markers of the Zika virus, but flags the fact that this is a mutated strain that could be resistant to existing vaccines. She reports the information to her colleague, Franco, at the nearest hospital and to public health authorities. They need to know that this could signal the start of an outbreak.

This scenario is imaginary, but researchers around the world now use pocket-size genomic sequencers to rapidly detect resistant pathogenic strains in hospitals, explore microbial diversity in Antarctic ice valleys, and diagnose infectious agents in food supply and aboard spaceships (the device works in microgravity). In 2015, for example, Johanna Rhodes from Imperial College London relied on portable sequencers to identify the genetic makeup of Candida auris, a multidrug-resistant fungal pathogen that had caused an outbreak in a London hospital. The same year, a research team from Birmingham University flew to Guinea and used the same technology to detect strains of Ebola in human blood. In a few months, they had sequenced 142 Ebola genomes on the spot, producing results less than 24 hours after receiving an Ebola-positive sample.

But what if sequencer-equipped researchers were able to transmit what theyre learning directly to others? Imagine students in universities becoming the first sequencing line of defense by detecting bacteria resistant to antibiotics and educating their neighbors about them. Imagine the same neighbors equipped with portable sequencers to identify microorganisms in soils capable of fighting resistant pathogens. These new bio-citizens would be socially responsible actors who use biology as the main language to understand themselves and the world around them, playing an increasing role in protecting global health and ecosystems.

This is the utopian version of what visionaries call the second genomic revolution, where sequencing our genomes and those of other species becomes a pervasive data market in which DNA is the primary currency. Yet we must remain lucid about who will primarily contribute and who will reap the rewards of streaming our DNA to the cloud. The way forward is to make sure that this trove of data does not benefit only those who already reign over our digital infrastructures but build counter powers, global commons where citizens can learn to turn their own data into innovations.

The new lab-in-your-hand technology is the product of Oxford Nanopore Technologies, a British company, whose ambition is to democratize genomic sequencing. Its sequencer, called MinION is as small as a USB-stick and easy to use for any apprentice scientist who knows how to prepare samples of blood, bodily fluids or water to be fed into the device. Such preparation is easily done by amateur biologists in DIY bio labs. Researchers and clinicians across the world have now adopted these portable sequencers, some to detect foodborne outbreaks in hospital, others to analyze the DNA of new species in the jungle. As early skepticism fades away, industry giants (Illumina and Roche) and newcomers (Genapsys) alike are showing interest in following Oxford Nanopores head start in portable sequencing.

If the ambition is to promote more distributed use of genomic sequencing, users also need a ready-made platform for interpreting genetic data. Oxford Nanopore has designed an intelligent cloud lab, Metrichor, to be used for genomics data storage in conjunction with smartphone apps that interpret the meaning of DNA sequences.

The convergence of automation technologies, intelligent algorithms and cloud computing is progressively making genomics available to less skilled actors. While this does not necessarily ensure democratization, it does enable us to imagine it. And so, what if it actually happens?

The world around us would be equipped with increasingly sophisticated bio-sensing capacity: the ability to identify the genetic composition of our bodily fluids, species surrounding us and microorganisms on our skins and in our backyards. Portable genomic sequencers in our pockets and cell phones would become part of our networks of sensorswhat we already call the Internet of things (IoT).

The attributes of a new bio-citizen then look like this: scientists, patients, congressmen, employeeseveryonewill be monitoring the DNA of their own bodies on shared cloud labs. Portable genomic sequencers, the size of a USB stick and connected to our smartphones, would also be integrated to our most strategic technical systems, including agro-food facilities, airports, battlefields and hospitals. These DNA-reading sensors would identify the nature, transmission paths and mutations of deadly viruses, engineered bacteria and even forgotten lethal pathogens that could one day be freed by the melting permafrost. In their home, individuals would have access to liquid biopsies blood tests that could track their most vital biomarkers and identify at an early stage the pieces of DNA shredded by a cancer tumor or a viral agent. If millions of citizens were streaming these data to the cloud, they would build the most powerful data set for preventive and precision medicine the world has ever known. The genetic identity of any living thing, then, acquires a new life on the Internet. We enter the age of the Internet of living things (IoLT).

The amount of genomics data to be stored, curated and protected in the digital bio-space will keep growing, requiring powerful and expensive computing platforms. It will create a complex architecture with new needs related to the governance of such an increasingly data-driven society.

Without access to the cloud, as provided by Google and Amazon, many biomedical projectsfrom J. Craig Venters Human Longevity to genome-wide analyses focused on autism and Alzheimerscould hardly have taken shape. Google and Amazon offer a deal too tempting to refuse: the most sophisticated cybersecurity strategies as well as analytical speed and power. These services seldom come free; universities, companiesin the future, hospitals, doctors and citizenswill likely keep paying for each genome to be stored, analyzed or transferred to a different repository.

Another hard truth is that most analyses of genomic data are comparative, meaning what can be learned about a new and potentially important genomic sequence is based on some existing point of reference. Yet, genomic sequences of interest risk being held by private databasesthink 23andMethat gain a competitive advantage by selling access to their genetic gold.

As a consequence of the growing number of players that may be involved in the process of generating, collecting and processing the data, determining the legal ownership of such data may prove increasingly complex. Like our personal information gathered by the IoT, our genetic secrets might end up trapped by 10,000-word-long consumer agreements.

The powerful and lucrative alliance between genetics and a data-driven society has already made tech giants in Silicon Valley and Seattle the new masters of our digital identities. If we consider the current privatization of consumers data and the erosion of digital privacy, it is not difficult to imagine, in the future, large corporations using their vast computing and machine-learning platforms to commodify continuous streams of genetic data about humans and ecosystems. Global conflicts over ownership would have to be balanced by open-source efforts to ensure that research, data and technological tools primarily serve the public good. The Global Alliance for Genomics and Health is an example, a thriving effort to share genomes across disciplinary and geographical boundaries.

For the Internet of living things to realize its promises, U.S. policymakers and regulators, in collaboration with technologists, should have an ambitious conversation about global data commons. How open and resilient should our big data architectures be, in particular those used for monitoring vital public health and environmental factors?

Experts will also need to consider the challenge and cost of ensuring accuracy when dealing with biological and microbial samples. One can imagine an IoLT node monitoring for Ebola virus and sending a positive signal, which, if not substantiated, could cause panic. The potential of monitoring for biological threats is enormous, but methods to validate data and address personal and collective liability issues are needed.

What is more troubling as we slowly enter the age of ubiquitous genomics sequencing is that we face an increasing socio-economic disparity between the technological elitesSilicon Valley or the new Shenzhen tech Eldoradoand the majority of citizens, the ones who provide data. While I have no hope that this gap will soon be closed, the next decade will first tell us if the new bio-citizen is just in our imagination.

Read this article:
The Internet of Living Things - Scientific American (blog)